Sodium-glucose co-transporter 2 inhibitors and heart failure—the present and the future
Abstract Type 2 diabetes mellitus is associated with an increased risk of heart failure. The prevalence of type 2 diabetes mellitus is on an upward trend. Heart failure represents one of the major causes for hospitalisation and mortality despite advances in management. Recent cardiovascular outcome trials have demonstrated that sodium-glucose co-transporter 2 inhibitors, which were introduced to the market in 2013, can incur a clinically significant risk reduction in heart failure outcomes in such patients. In this review, we discuss the epidemiology and pathophysiology of heart failure in diabetes and explore the landmark trials, the potential mechanisms of benefit of SGLT-2 inhibitors in heart failure, how the trials have led to major changes in treatment guidelines, and future potential directions for use of these drugs, including in those without diabetes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Heart failure reviews - 26(2020), 4 vom: 04. Feb., Seite 953-960 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nana, Melanie [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Cardiovascular outcomes |
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2020 |
|---|
| doi: |
10.1007/s10741-020-09925-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR044134967 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR044134967 | ||
| 003 | DE-627 | ||
| 005 | 20230519075833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210526s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10741-020-09925-z |2 doi | |
| 035 | |a (DE-627)SPR044134967 | ||
| 035 | |a (DE-599)SPRs10741-020-09925-z-e | ||
| 035 | |a (SPR)s10741-020-09925-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.85 |2 bkl | ||
| 100 | 1 | |a Nana, Melanie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sodium-glucose co-transporter 2 inhibitors and heart failure—the present and the future |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2020 | ||
| 520 | |a Abstract Type 2 diabetes mellitus is associated with an increased risk of heart failure. The prevalence of type 2 diabetes mellitus is on an upward trend. Heart failure represents one of the major causes for hospitalisation and mortality despite advances in management. Recent cardiovascular outcome trials have demonstrated that sodium-glucose co-transporter 2 inhibitors, which were introduced to the market in 2013, can incur a clinically significant risk reduction in heart failure outcomes in such patients. In this review, we discuss the epidemiology and pathophysiology of heart failure in diabetes and explore the landmark trials, the potential mechanisms of benefit of SGLT-2 inhibitors in heart failure, how the trials have led to major changes in treatment guidelines, and future potential directions for use of these drugs, including in those without diabetes. | ||
| 650 | 4 | |a Heart failure |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sodium-glucose co-transporter 2 inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Type 2 diabetes mellitus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cardiovascular outcomes |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Morgan, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a Bondugulapati, L. N. Rao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heart failure reviews |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1996 |g 26(2020), 4 vom: 04. Feb., Seite 953-960 |w (DE-627)SPR012861839 |w (DE-600)2006431-7 |x 1573-7322 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g number:4 |g day:04 |g month:02 |g pages:953-960 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10741-020-09925-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.85 |q ASE |
| 951 | |a AR | ||
| 952 | |d 26 |j 2020 |e 4 |b 04 |c 02 |h 953-960 | ||